SCHEMBL1630752

SCHEMBL1630752

Cc1ccc(C(=O)c2ccccc2F)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.65
ALDH1A1 P00352 4/20 0.56
LMNA P02545 2/20 0.56
TDP1 Q9NUW8 2/20 0.54
GAA P10253 2/20 0.53
ABCC9 O60706 1/20 0.52
ABCC8 Q09428 1/20 0.52
KCNJ11 Q14654 1/20 0.52
KCNJ8 Q15842 1/20 0.52
CES2 O00748 2/20 0.52
CES1 P23141 2/20 0.52
POLB P06746 1/20 0.51
SRD5A2 P31213 1/20 0.48
ALOX15 P16050 1/20 0.48
MAPT P10636 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
KDM4E B2RXH2 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10759830 0.90 CES2 (0.62) AKR1C3ALDH1A1LMNATDP1GAA
SCHEMBL11189754 0.86 AKR1C3 (0.84) AKR1C3ALDH1A1LMNATDP1CES2
SCHEMBL1631863 0.85 AKR1C3 (0.56) AKR1C3ALDH1A1LMNATDP1GAA
SCHEMBL9507199 0.84 CDC25B (0.60) AKR1C3ALDH1A1LMNATDP1GAA
SCHEMBL29377967 0.84 CES2 (0.56) AKR1C3ALDH1A1LMNATDP1GAA
SCHEMBL896769 0.84 CES2 (0.56) AKR1C3ALDH1A1LMNATDP1GAA
SCHEMBL333008 0.84 AKR1C3 (0.61) AKR1C3ALDH1A1LMNATDP1GAA
SCHEMBL29433447 0.84 AKR1C3 (0.61) AKR1C3ALDH1A1LMNATDP1GAA
SCHEMBL9409836 0.82 CES2 (0.54) ALDH1A1LMNATDP1GAAABCC9
Methylamine SCHEMBL10828909 0.82 GAA (0.57) AKR1C3ALDH1A1LMNATDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470872-B2 Compounds with activity at estrogen receptors ACADIA PHARMACEUTICALS INC. (US) 2013-06-25 US disclosed
US-20120088825-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2012-04-12 US disclosed
US-8101651-B2 Compounds with activity at estrogen receptors ACADIA PHARMACEUTICALS INC. (US) 2012-01-24 US disclosed
US-20090131510-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ACADIA PHARMACEUTICALS INC. 2009-05-21 US disclosed
EP-0628064-B2 PHOTOCHROMIC NAPHTHOPYRANS TRANSITIONS OPTICAL INC (US) 2003-12-10 EP disclosed
EP-0628064-B1 PHOTOCHROMIC NAPHTHOPYRANS TRANSITIONS OPTICAL INC (US) 1999-04-07 EP disclosed
US-5585042-A REVERSIBLE CHANGE IN COLOR WHEN EXPOSURED TO ULTRAVIOLET RADIATION TRANSITIONS OPTICAL, INC. (US) 1996-12-17 US disclosed
EP-0628064-A4 PHOTOCHROMIC NAPHTHOPYRANS. PPG INDUSTRIES INC (US) 1995-02-08 EP disclosed
EP-0628064-A1 PHOTOCHROMIC NAPHTHOPYRANS TRANSITIONS OPTICAL, INC. (US) 1994-12-14 EP disclosed
US-5369158-A And polymer TRANSITIONS OPTICAL, INC. (US) 1994-11-29 US disclosed
EP-0600318-A1 Asymmetric, halogenated benzophenones and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-08 EP disclosed
US-5300693-A Process for the preparation of 1,4-bis(4-fluorobenzoyl)-benzene HOECHST AKTIENGESELLSCHAFT (DE) 1994-04-05 US disclosed
WO-1993017071-A1 PHOTOCHROMIC NAPHTHOPYRANS PPG INDUSTRIES, INC. (US) 1993-09-02 WO disclosed
US-5238981-A PHOTOCHROMIC NAPHTHOPYRANS TRANSITIONS OPTICAL, INC. (US) 1993-08-24 US disclosed
EP-0531339-A1 PROCESS FOR PRODUCING 1,4-BIS-(FLUORBENZOYL)-BENZOL HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-17 EP disclosed
WO-1991018862-A1 PROCESS FOR PRODUCING 1,4-BIS-(FLUORBENZOYL)-BENZOL HOECHST AKTIENGESELLSCHAFT (DE) 1991-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088825-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ESRRB, ESR2, ESRRA AKR1C3 613/4885ALDH1A1 566/4885LMNA 2718/4885
US-20090131510-A1 COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS ESRRB, ESR2, ESRRA AKR1C3 613/4885ALDH1A1 566/4885LMNA 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.